Rykina-Tameeva Nadya, Samra Jaswinder S, Sahni Sumit, Mittal Anubhav
Northern Clinical School, University of Sydney, St Leonards 2065, Australia.
World J Gastrointest Surg. 2022 Oct 27;14(10):1089-1106. doi: 10.4240/wjgs.v14.i10.1089.
Clinically relevant postoperative pancreatic fistula (CR-POPF) has continued to compromise patient recovery post-pancreatectomy despite decades of research seeking to improve risk prediction and diagnosis. The current diagnostic criteria for CR-POPF requires elevated drain fluid amylase to present alongside POPF-related complications including infection, haemorrhage and organ failure. These worrying sequelae necessitate earlier and easily obtainable biomarkers capable of reflecting evolving CR-POPF. Drain fluid has recently emerged as a promising source of biomarkers as it is derived from the pancreas and hence, capable of reflecting its postoperative condition. The present review aims to summarise the current knowledge of CR-POPF drain fluid biomarkers and identify gaps in the field to invigorate future research in this critical area of clinical need. These findings may provide robust diagnostic alternatives for CR-POPF and hence, to clarify their clinical utility require further reports detailing their diagnostic and/or predictive accuracy.
尽管数十年来一直在研究如何改善风险预测和诊断,但临床相关的术后胰瘘(CR-POPF)仍然影响着胰腺切除术后患者的恢复。目前CR-POPF的诊断标准要求引流液淀粉酶升高,并伴有与POPF相关的并发症,包括感染、出血和器官衰竭。这些令人担忧的后遗症需要能够反映CR-POPF进展情况的早期且易于获取的生物标志物。引流液最近已成为一种有前景的生物标志物来源,因为它来自胰腺,因此能够反映其术后状况。本综述旨在总结目前关于CR-POPF引流液生物标志物的知识,并找出该领域的空白,以推动这一临床需求关键领域的未来研究。这些发现可能为CR-POPF提供可靠的诊断替代方法,因此,要阐明它们的临床效用,需要进一步的报告详细说明其诊断和/或预测准确性。